Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ENLIE Pharmaceutical JSCHSTC:BCP 25 Earnings per Share (Diluted) is ₫ as of . 20. GuruFocus rates HSTC:BCP with a GF Score™ of 25/100. Among 788 Drug Manufacturers companies, ENLIE Pharmaceutical JSC ranks worse than 126903.43% on this metric.
ENLIE Pharmaceutical JSC (HSTC:BCP) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
ENLIE Pharmaceutical JSC Earnings per Share (Diluted) Related Terms
ENLIE Pharmaceutical JSC Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for ENLIE Pharmaceutical JSC's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENLIE Pharmaceutical JSC Earnings per Share (Diluted) Chart
ENLIE Pharmaceutical JSC Annual Data
Trend
Earnings per Share (Diluted)
ENLIE Pharmaceutical JSC Semi-Annual Data
Earnings per Share (Diluted)
HSTC:BCP vs : Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ENLIE Pharmaceutical JSC's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENLIE Pharmaceutical JSC PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ENLIE Pharmaceutical JSC's PE Ratio distribution charts can be found below:
* The bar in red indicates where ENLIE Pharmaceutical JSC's PE Ratio falls into.
ENLIE Pharmaceutical JSC Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
ENLIE Pharmaceutical JSC's Earnings Per Share (Diluted) for the fiscal year that ended in . 20 is calculated as
What does a Earnings per Share (Diluted) of ₫ mean?
ENLIE Pharmaceutical JSC (HSTC:BCP) has a Earnings per Share (Diluted) of ₫ as of . 20. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on ENLIE Pharmaceutical JSC and its competitors. According to the industry distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 788 companies in the Drug Manufacturers industry.
Is ENLIE Pharmaceutical JSC's Earnings per Share (Diluted) too high?
ENLIE Pharmaceutical JSC's current Earnings per Share (Diluted) is ₫. Based on the distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 788 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ENLIE Pharmaceutical JSC has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENLIE Pharmaceutical JSC's Earnings per Share (Diluted) compare to ?
According to the Drug Manufacturers industry distribution chart, ENLIE Pharmaceutical JSC ranks #999999 out of 788 companies for Earnings per Share (Diluted). This places ENLIE Pharmaceutical JSC in the lower half of its industry. The industry median Earnings per Share (Diluted) is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.65, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on ENLIE Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENLIE Pharmaceutical JSC's current Earnings per Share (Diluted) is ₫. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENLIE Pharmaceutical JSC stock overvalued right now?
ENLIE Pharmaceutical JSC (HSTC:BCP) has a current Earnings per Share (Diluted) of ₫. The current Earnings per Share (Diluted) is ₫. ENLIE Pharmaceutical JSC's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For ENLIE Pharmaceutical JSC (HSTC:BCP), the current Earnings per Share (Diluted) is ₫ as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENLIE Pharmaceutical JSC is engaged in the production and trading of pharmaceuticals, medical supplies, cosmetics, foods, and functional foods. It is also engaged in the wholesale of other installation materials and equipment in the construction.
25GF Score
Get the complete analysis for HSTC:BCP
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:BCP has been successfully added to your 
